Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2012-06-21

Clinical Trial Update: BEZ235 Trial in Patients With Advanced Endometrial Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of BEZ235 in patients with advanced endometrial carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BEZ235 (dactolisib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Endometrial Cancer | Phase 2 | Status: WITHDRAWN